Evaluation of pharmacodynamics and safety of teneligliptin in type 2 diabetic patients with chronic renal dysfunctio
Not Applicable
- Conditions
- Patients with Type 2 diabetes [chronic renal dysfunction (CKD Stage:over G3b)]
- Registration Number
- JPRN-UMIN000010343
- Lead Sponsor
- Kitano Hospital, The Tazuke Kofukai Medical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1)Type 1 diabetes,diabetes arising from the failure of pancreas,or secondary diabetes (eg. Cushing's syndrome and acromegaly) 2) Patient correspond to contraindications of teneligliptin 3) Excessive alcohol addicts: patient who take average net more than 60 g alcohol every single day (more than following: 3 bottles of sake, 1 with shochu, 3 bottles of beer, 3 glasses of whiskey or brandy(double),and 5 glasses of wine) 4) Pregnant, lactating, possible pregnant patient 5) Patient judged as ineligible for this study by the researcher
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method